Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 356.24M P/E - EPS this Y 7.70% Ern Qtrly Grth -
Income -110.78M Forward P/E -3.76 EPS next Y -15.50% 50D Avg Chg 14.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 52.00%
Dividend N/A Price/Book 1.76 EPS next 5Y - 52W High Chg -12.00%
Recommedations 1.30 Quick Ratio 14.66 Shares Outstanding 70.54M 52W Low Chg 235.00%
Insider Own 9.13% ROA -25.20% Shares Float 42.72M Beta 1.11
Inst Own 98.93% ROE -38.79% Shares Shorted/Prior 12.38M/12.86M Price 7.90
Gross Margin - Profit Margin - Avg. Volume 401,632 Target Price 18.75
Oper. Margin - Earnings Date Nov 4 Volume 224,550 Change -2.59%
About Oric Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Oric Pharmaceuticals, Inc. News
11/12/24 ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
11/04/24 ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
11/01/24 ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
10/23/24 ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
10/15/24 Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
10/09/24 ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
09/14/24 ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock
08/12/24 ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates
08/05/24 ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs
07/17/24 ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
07/16/24 ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
07/09/24 Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors
07/08/24 Why Is ORIC Pharmaceuticals, Inc. (ORIC) Among the Most Shorted Stocks That Are Loved by Analysts?
05/08/24 We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
05/06/24 ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
04/15/24 ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
04/08/24 ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
03/26/24 How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%
03/12/24 ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results
03/11/24 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
ORIC Chatroom

User Image Bruno_Jordan Posted - 1 day ago

$OLMA $IRWD $ORIC LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image BondbutnotJames Posted - 6 days ago

$ORIC what happened here

User Image Thestocktraderhubzee Posted - 2 weeks ago

WATCHLIST NOV 01 2024 $AVDL HC Wainwright & Co. Reiterates Buy on Avadel Pharmaceuticals, Maintains $27 Price Target $ORIC Wells Fargo Initiates Coverage On ORIC Pharmaceuticals with Overweight Rating, Announces Price Target of $20 $ADP RBC Capital Maintains Sector Perform on Automatic Data Processing, Raises Price Target to $315 $INFA UBS Maintains Neutral on Informatica, Raises Price Target to $30 $FTV RBC Capital Maintains Sector Perform on Fortive, Lowers Price Target to $77

User Image IN0V8 Posted - 10/31/24

$ORIC Opportunity Jonestrading initiates coverage with buy rating; PT $17 Wells Fargo initiates coverage with overweight rating Wells Fargo initiates coverage with target price $20

User Image Fugazi_ Posted - 10/31/24

$ORIC interesting movement pre-mkt

User Image Fugazi_ Posted - 10/23/24

$ORIC this had the biggest call volume since march, will be following this closely. Average daily volume is around 1-5 barely. Could post a PLCE move, 22+ days to cover.

User Image swingingtech Posted - 10/23/24

$ORIC $THO $TMUS https://wallstreetwaves.com/notable-wednesday-option-activity-oric-tho-tmus/

User Image OpenOutcrier Posted - 10/23/24

$ORIC (+8.5% pre) ORIC® Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics https://ooc.bz/l/45524

User Image Godwinsol Posted - 10/23/24

$ORIC 100% tumor regression and CR https://www.tradingview.com/news/reuters.com,2024-10-23:newsml_GNX6C7TFZ:0-oric-pharmaceuticals-presents-data-further-supporting-potential-best-in-class-profile-of-oric-114-to-treat-egfr-exon-20-insertions-and-other-atypical-mutations-at-the-eortc-nci-aacr-symposium-on-molecular-targets-and-cancer-therapeutics/

User Image Godwinsol Posted - 10/22/24

$ORIC tomorrow ORIC presents

User Image themacromindset Posted - 1 month ago

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics $ORIC

User Image themacromindset Posted - 1 month ago

ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics $ORIC

User Image BobBuran Posted - 1 month ago

Tuesday This is the ONLY post showing a total of about 50 of my buy stop orders (LE for long entry) above the market for today. Already bot past ten minutes: $ORIC $CRMD $SAVA $CVNA #stocks

User Image vjtweet Posted - 09/27/24

$ORIC bought it.

User Image Himel92 Posted - 2 months ago

The Last month Performance for $ORIC Opening Price: $10.10 Closing Price: $10.67 Highest Price: $10.96 Lowest Price: $8.91 Percentage Change: 5.64% Data analyst: AITX

User Image BobBuran Posted - 2 months ago

Thursday This is the second of TWO posts showing a total of about 50 of my buy stop orders (LE for long entry) above the market for today. Already bot past ten minutes: $PRLD $ORIC $POET #stocks

User Image BobBuran Posted - 2 months ago

Thursday This is the first of TWO posts showing a total of about 50 of my buy stop orders (LE for long entry) above the market for today. Already bot past ten minutes: $PRLD $ORIC $POET #stocks

User Image History101 Posted - 2 months ago

$ORIC

User Image Stock_Titan Posted - 2 months ago

$ORIC OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration https://www.stocktitan.net/news/ORIC/open-bench-and-oric-pharmaceuticals-launch-success-driven-discovery-t0oj8qi2otq6.html

User Image History101 Posted - 2 months ago

$ORIC starting position, $10.13. GLTALs!!

User Image Bloopybrand Posted - 2 months ago

$MCVT wow a lot of people are watching this now. $ORIC and $FOR worth watching

User Image History101 Posted - 2 months ago

$ORIC 564 watching 9/15/2024

User Image History101 Posted - 2 months ago

$ORIC short interest, per Barron's, 8/30/2024: 12.67MM shares short (down 1.5% from 8/15/2024) 27.3% of float 22.2 days to cover

User Image ShortSqueezeRILY Posted - 2 months ago

$WOLF $ORIC

User Image Telefon Posted - 2 months ago

$ELTP Elite Pharmaceuticals - Drugs Awaiting Launch and Total Market Value Methotrexate ($63.4M): Recently FDA approved, launching this quarter. Generic APAP with Codeine ($45M): Brand name Tylenol with Codeine, launching 6-8 weeks after Methotrexate. Oxy APAP ($500M): Generic Percocet, launching 6-8 weeks after APAP with Codeine. Hydro APAP ($477M): Generic Norco, launching after Oxy APAP. Methadone ($30M): Launching after Hydro APAP. Generic Vyvanse ($5.1B): Pending FDA approval, will take priority upon approval. Total Potential Market Value: $6.215 Billion $ORIC $COLL $TARS $PHAT

User Image BobBuran Posted - 08/28/24

Wednesday This is the second of TWO posts showing a total of about 50 of my buy stop orders (LE for long entry) above the market for today. Already bot past ten minutes: $VRAX $NEON $ORIC #stocks

User Image WrappedLunatic Posted - 3 months ago

$TEM $LUNR $ORIC This man may be on to something.

User Image SqueezeFinder1 Posted - 3 months ago

Here are some tickers with nice charts and/or upcoming scheduled events to keep on your radar going forward, and their respective confidence levels ranging from 1-3 🍊. (Please note that confidence levels are subjective to personal observation and strategy, and should be reviewed individually prior to assuming success potential) 1. $TEM Squeezability Score: 68% Juice Target: 89.8 Confidence: 🍊 🍊 🍊 Major Support: 38.0 Major Resistance: 48.0 Mentions (30D): 9 Event/Condition: ATH / price discovery 2. $LUNR Squeezability Score: 67% Juice Target: 10.0 Confidence: 🍊 🍊 Major Support: 3.2 Major Resistance: 4.6 Mentions (30D): 1 Event/Condition: Double bottom + sympathy (space) 3. $ORIC Squeezability Score: 61% Juice Target: 18.3 Confidence: 🍊 🍊 Major Support: 9.0 Major Resistance: 12.1 Mentions (30D): 3 Event/Condition: Inverse H&S + elevated rel vol Check my profile for more ideas and daily alerts :)

User Image StockInvest_us Posted - 3 months ago

Signal alert: $ORIC - PivotPoint bottom https://stockinvest.us/l/BAtP9mgp9B

User Image BobBuran Posted - 3 months ago

Thursday Dow opens +506 and we open carrying +4,935 with $MEDS $JANX and $ORIC #stocks

Analyst Ratings
Cantor Fitzgerald Overweight Sep 23, 24
HC Wainwright & Co. Buy Sep 18, 24
Wedbush Outperform Sep 10, 24
Cantor Fitzgerald Overweight Sep 9, 24
Stifel Buy Sep 6, 24
HC Wainwright & Co. Buy Aug 14, 24
Wedbush Outperform Aug 13, 24
Oppenheimer Outperform Aug 13, 24
Wedbush Outperform Jul 17, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Multani Pratik S Chief Medical Office.. Chief Medical Officer Dec 15 Sell 8.59 5,282 45,372 23,809 12/19/23
Multani Pratik S Chief Medical Office.. Chief Medical Officer Dec 15 Option 0 14,042 29,091 12/19/23
Piscitelli Dominic Chief Financial Offi.. Chief Financial Officer Dec 15 Sell 8.58 5,282 45,320 83,809 12/19/23
Piscitelli Dominic Chief Financial Offi.. Chief Financial Officer Dec 15 Option 0 14,042 89,091 12/19/23
Chacko Jacob President and CEO President and CEO Dec 15 Sell 8.58 14,539 124,745 808,544 12/19/23
Chacko Jacob President and CEO President and CEO Dec 15 Option 0 38,667 823,083 12/19/23
Chacko Jacob President and CEO President and CEO Jul 10 Sell 8.01 15,664 125,469 780,652 07/11/23
Chacko Jacob President and CEO President and CEO Jun 26 Sell 8.0281 20,000 160,562 800,652 06/28/23
Multani Pratik S Chief Medical Office.. Chief Medical Officer Dec 15 Option 0 6,041 9,512 12/16/22
Multani Pratik S Chief Medical Office.. Chief Medical Officer Dec 15 Sell 3.25 2,089 6,789 7,423 12/16/22
Piscitelli Dominic Chief Financial Offi.. Chief Financial Officer Dec 15 Option 0 6,041 69,512 12/16/22
Piscitelli Dominic Chief Financial Offi.. Chief Financial Officer Dec 15 Sell 3.25 2,089 6,789 67,423 12/16/22
Chacko Jacob President and CEO President and CEO Dec 15 Option 0 16,666 822,789 12/16/22
Chacko Jacob President and CEO President and CEO Dec 15 Sell 3.25 5,764 18,733 817,025 12/16/22
Chacko Jacob President and CEO President and CEO May 11 Buy 2.82 450,000 1,269,000 802,652 05/13/22
Piscitelli Dominic Chief Financial Offi.. Chief Financial Officer Mar 31 Buy 5.3604 60,000 321,624 60,000 03/31/22
Chacko Jacob President and CEO President and CEO Mar 23 Buy 4.85 350,000 1,697,500 352,652 03/25/22
Heyman Richard A. Director Director Sep 16 Sell 25.04 1,388 34,756 216,272 09/16/21
Chacko Jacob President and CEO President and CEO Sep 16 Sell 25.05 8,156 204,308 2,652 09/16/21
Heyman Richard A. Director Director May 24 Sell 25.11 1,400 35,154 219,826 05/24/21
SCHELLER RICHARD H Director Director May 24 Sell 25.09 1,990 49,929 39,092 05/24/21
Chacko Jacob President and CEO President and CEO May 24 Sell 25.09 7,270 182,404 23,132 05/24/21
Heyman Richard A. Director Director May 18 Sell 25.23 5,874 148,201 221,226 05/18/21
Heyman Richard A. Director Director Apr 30 Sell 25.17 200 5,034 227,200 04/30/21
SCHELLER RICHARD H Director Director Apr 30 Sell 25.15 300 7,545 49,500 04/30/21
Chacko Jacob President and CEO President and CEO Apr 30 Sell 25.15 1,300 32,695 60,400 04/30/21
GORDON CARL L Director Director Mar 31 Sell 23.62 103,424 2,442,875 2,212,571 03/31/21
- - - Mar 31 Sell 23.62 103,424 2,442,875 2,212,571 03/31/21
GORDON CARL L Director Director Mar 26 Sell 24.46 112,298 2,746,809 2,315,995 03/26/21
GORDON CARL L Director Director Mar 23 Sell 25.75 32,940 848,205 2,428,293 03/23/21
- - - Mar 23 Sell 25.75 32,940 848,205 2,428,293 03/23/21